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OBJECTIVES This study examines the efficacy of FTY720 (FTY), a new immunosuppressor, in the
treatment of acute viral myocarditis in a murine model.
BACKGROUND Immunosuppressive agents have no proven therapeutic efficacy in experimental or clinical
myocarditis.
METHODS Encephalomyocarditis virus was inoculated i.p. in DBA/2 mice on day 0. Postinoculation
treatment consisted of FTY 10 mg/kg/day p.o. (FTY group), or cyclosporine A (CsA)
40 mg/kg/day p.o. (CsA group) or distilled water p.o. only (control group). Survival until day
14, as well as cardiac histopathology, virus concentrations, cytokines (interleukin [IL]-2,
IL-12, interferon [IFN]-gamma and tumor necrosis factor [TNF]-alpha) and nitric oxide
(NO) on day 5 were examined.
RESULTS In the control and CsA groups, all mice died within 10 and 7 days, respectively. However, in
the FTY group, 27% of the animals survived up to day 14. Compared with the control group,
1) histological scores were significantly lower in the FTY group but unchanged in the CsA
group; 2) virus concentration was significantly higher in the CsA group but not in the FTY
group; 3) expressions of IL-2, IL-12 and IFN-gamma in the heart were suppressed in both
the FTY and CsA groups, though suppression was weaker in the FTY group; 4) TNF-alpha
and NO were significantly increased in the CsA group but not in the FTY group.
CONCLUSIONS FTY720 had a significant therapeutic effect in acute experimental myocarditis without
inducing excessive virus replication. This report is the first to describe a beneficial effect by an
immunosuppressive agent in the treatment of acute viral myocarditis. (J Am Coll Cardiol
2001;37:1713–8) © 2001 by the American College of Cardiology
Recent developments in the molecular analysis of autopsy
and biopsy specimens have clarified the relationship between
viral myocarditis and dilated cardiomyopathy (1,2). Therefore,
treatments targeted toward viral infections are becoming im-
portant in the prevention of heart failure complicating myo-
carditis. However, despite intensive experimental and clinical
research, specific therapies remain to be developed. Because
both the direct cytopathic effects of the virus and the host
immune response that it induces appear to be responsible for
the manifestations of viral myocarditis (3), therapeutic effects
have been expected from immunosuppression, a hypothesis
supported by anecdotal, isolated case reports. However, treat-
ment of myocarditis with immunosuppressors such as cortico-
steroids (4,5), cyclosporine A (CsA) (6–8) or FK506 (tacroli-
mus) (9) has been ineffective experimentally and in the recent
clinical Myocarditis Treatment Trial (10).
The new synthetic immunosuppressor FTY720 (2-
amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydro-
chloride, FTY), a derivative of ISP-I (myriocin) isolated
from the fungus Isaria sinclairii (11,12), has unique prop-
erties, unlike those of CsA and FK506 or of corticosteroids
(13). Its precise mechanisms of action remain unclear,
though it has been shown to accelerate the sequestration of
circulating mature lymphocytes into lymph nodes and Pey-
er’s patches (14) and to decrease the number of peripheral
blood lymphocytes and their infiltration into target tissues
(15). In contrast to CsA and FK506, FTY does not suppress
the proliferative response of T cells (16) or the production of
IL-2 by lymphocytes in vitro (14). In experimental allogenic
transplantation models of skin (14,17,18), liver (18), kidney
(19) and heart (19,20), FTY has already been found as
effective as, or more effective than, CsA in promoting the
survival of allografts. Despite its importance in organ
transplantation, the efficacy of FTY against infectious
pathogens has been the object of only a few reports (21).
This study was performed to examine the efficacy of FTY
in the treatment of experimental acute viral myocarditis
induced by encephalomyocarditis virus (EMCV) in a mu-
rine model.
MATERIALS AND METHODS
Pharmaceuticals. FTY, supplied as dry powder by Yoshi-
tomi Pharmaceutical Industries, Ltd. (Osaka, Japan), was
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dissolved in sterile distilled water. Cyclosporine A was
purchased from Sigma Pharmaceuticals (St. Louis, Mis-
souri) and dissolved in olive oil (20).
Experimental viral myocarditis. Twenty-eight-day-old
male DBA/2 mice were purchased from Shizuoka Agricul-
tural Cooperation Association (Shizuoka, Japan) and
housed in a special pathogen-free animal facility of the
Kyoto University Hospital. The experiments were per-
formed in a well-established murine model of EMCV-
induced myocarditis (22). Briefly, the mice were inoculated
intraperitoneally with 10 plaque-forming units (pfu) of the
myocardiotrophic (M) variant of EMCV on day 0 and
observed daily. Starting on day 0, FTY was daily adminis-
tered orally in a dose of 10 mg/kg/day in one group of mice
(FTY group), CsA was daily administered orally in a dose of
40 mg/kg/day in an other group (CsA group) and control
mice received distilled water only (control group) (20). Each
drug, or the distilled water, was administered via a gastric
tube to guarantee reliable delivery. All experiments were
performed in accordance with the Guidelines for Animal
Experiments of Kyoto University.
Survival study. In the survival experiments, the animals
(nine in the CsA group, 21 in the FTY group, 22 in the
control group) were observed daily between day 0 and day
14. In another series of experiments, the same doses of CsA
or FTY were administered to uninfected mice (five in each
group) in order to examine the effects of the drugs on
survival in absence of infection.
Histopathologic examination. For histopathologic stud-
ies, hearts from surviving mice (six in the CsA group, eight
in the FTY group, nine in the control group) were harvested
on day 5, fixed in 10% formalin and embedded in paraffin.
The ventricle was sliced transversally, stained with hema-
toxylin and eosin, and examined by light microscopy. Extent
of cellular infiltration and myocardial necrosis were graded
as follows: 0 5 no lesion; 11 5 lesions involving ,25% of
the myocardium; 21 5 lesions involving 25% to 50% of the
myocardium; 31 5 lesions involving 50% to 75% of the
myocardium; 41 5 lesions involving .75% of the myocar-
dium. Extent of infiltration and necrosis was scored blindly
by two independent trained observers, whose scores were
averaged. The details of the method have been described
previously (23). In another series of experiments, the same
doses of CsA or FTY were administered to uninfected mice
(five in each group) to examine the effects of the drugs on
histopathology in absence of infection.
Intramyocardial virus concentration. For the measure-
ments of intramyocardial virus concentration, the ventricles
from surviving mice (five in the CsA group, seven in the
FTY group, eight in the control group) were harvested
aseptically on day 5, weighed, and homogenized in 1 ml
of phosphate buffered saline. After centrifugation at
14,000 rpm for 20 min at 4°C, 0.1 ml of supernatant was
inoculated into human amnion FL cell monolayers for
60 min at 37°C in 5% CO2. The cells were overlaid with
3 ml of medium containing 4% fetal calf serum and 1%
methylcellulose. After 20 h of incubation at 37°C in a
humidified atmosphere containing 5% CO2, the cells were
fixed with acetic acid and methanol (in a ratio of 1:2) and
stained with 1% crystal violet, and the plaques were counted
under an inverted microscope (23). If the plaques were too
numerous to count, the assay was repeated after appropriate
dilution of the supernatants with Dulbecco’s modified
Eagle’s medium (GIBCO BRL, New York, New York).
Each value represents the average of two experiments.
Myocardial virus concentration is expressed as plaque form-
ing units/g of heart.
Intracardiac cytokine assay. For assays of intracardiac
cytokine, the ventricles from surviving mice (six in the CsA
group, seven in the FTY group, eight in the control group)
were harvested on day 5, homogenized in 1 ml PBS solution
with an ultrasonic homogenizer (Astrason Ultrasonic Liq-
uid Processor, model XL2020, MISONIX Inc., Farming-
dale, New York) and centrifuged at 14,000 rpm for 20 min
at 4°C, and the supernatant was used for the assay of IL-2,
IL-12, IFN-gamma and TNF-alpha. Each cytokine protein
level was measured by enzyme-linked immunosorbent assay
(24) with commercially available kits according to each
manufacturer’s instructions. Enzyme-linked immunosor-
bent assay kits for mouse IL-2 and IFN-gamma were
purchased from GENZYME Corporation (Cambridge,
Massachusetts) and kits for mouse IL-12 and TNF-alpha
from ENDOGEN Inc. (Cambridge, Massachusetts).
The total protein concentration in each supernatant was
also measured by the bicinchoninate acid method, and the
ratio of cytokine concentration/total protein concentration
was calculated (25). Each cytokine protein level was ex-
pressed as pg or ng/mg total protein.
Intracardiac nitric oxide assay. Intracardiac nitric oxide
(NO) content was measured by modified Griess assay in the
same supernatants as the intracardiac cytokines (25,26). In
brief, 50 ml of supernatant or standard nitrite was mixed
with 10 ml of 10 mM beta-NADPH, and 40 ml premixed
master mix (500 mM glucose-6-phosphate, 160 U/l
glucose-6-phosphate dehydrogenase, 80 U/l nitrate reduc-
tase, 0.2 mM phosphate buffer) was added and incubated for
45 min at 20°C. Subsequently, 50 ml of 1% sulfanilamide in
5% H3PO4 and 50 ml of 0.1% naphthylethylene diamine
dihydrochloride were also added and incubated for 10 min
at 20°C. The optical density was measured at 540 nm with
a microplate reader. Nitrite concentration in each sample
was calculated from standards. Measurements of all samples
Abbreviations and Acronyms
CsA 5 cyclosporine A
EMCV 5 encephalomyocarditis virus
FTY 5 FTY720
IFN 5 interferon
iNOS 5 inducible NO synthase
NO 5 nitric oxide
TNF 5 tumor necrosis factor
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and standards were made in duplicate. The NO content in
the heart was determined by dividing each nitrite concen-
tration by the total protein concentration in each superna-
tant, expressed as mM/mg protein.
Statistical analysis. Statistical analysis of survival rates was
performed by the Kaplan-Meier method, followed by Fish-
er’s protected least significant difference. Histopathological
scores; intracardiac virus concentrations; intracardiac IL-2,
IL-12, IFN-gamma and TNF-alpha protein levels and NO
content were compared by one-way ANOVA, followed by
Fisher’s protected least significant difference. A value of p ,
0.05 was considered significant. Data are expressed as
mean 6 SEM.
RESULTS
Effects of FTY720 and CsA on survival in EMCV-
infected mice. In the control group all mice died within 10
days. Cyclosporine A had a negative effect on survival rate,
because none of the mice in that group survived past day 7
(Fig. 1), a significantly worse outcome than in the control
group. In contrast, six of 22 mice (27%) treated with FTY
were alive on day 14 (p 5 0.051 vs. control, and p 5 0.0128
vs. CsA). In the experiments performed in uninfected mice,
all animals survived until day 14 after the administration of
either drug (data not shown).
Histopathologic examinations. In the CsA group, the
cellular infiltration score was lower, and the necrosis score
slightly higher than in the control group (1.50 6 0.26 vs.
2.00 6 0.19 for infiltration, and 2.00 6 0.32 vs. 1.89 6 0.23
for necrosis), though these differences were not statistically
significant. In contrast, the scores of both cellular infiltra-
tion and necrosis in the FTY group were significantly lower
than in the control group (1.06 6 0.19 vs. 2.00 6 0.19 for
infiltration and 1.00 6 0.19 vs. 1.89 6 0.23 for necrosis,
Figs. 2 and 3). In the uninfected mice, neither drug had an
apparent effect on the cardiac histology on day 5 (data not
shown).
Intramyocardial virus concentration. Cyclosporine A in-
creased virus replication in the heart 20-fold compared with
control measurements (9.94 6 6.30 3 107 vs. 5.18 6
2.73 3 106, Fig. 4). In contrast, FTY had no such effect on
virus replication (1.23 6 0.53 3 107 vs. 5.18 6 2.73 3 106,
Fig. 4).
Measurements of intracardiac IL-2, IL-12, IFN-gamma
and TNF-alpha. The effects of treatment with FTY and
CsA on intramyocardial cytokines expression are summa-
rized in Figure 5. Consistent with previous observations
(27), protein levels of intracardiac IL-2, known to be
associated with T-cell proliferation, were lower in both the
CsA and the FTY groups than in the control group.
However, the suppression of IL-2 in the FTY group was
less prominent than in the CsA group. Protein levels of
intracardiac IL-12, a Th1-specific cytokine (28), were
Figure 1. Fourteen-day cumulative survival after encephalomyocarditis
virus inoculation in FTY720 treated mice (open circles), versus cyclospor-
ine A-treated mice (filled circles) versus control mice (filled squares).
Figure 2. Myocardial histopathologic scores for cellular infiltration (A) and
necrosis (B) on day 5 after encephalomyocarditis virus inoculation in
surviving mice. *p , 0.05; **p , 0.01. CsA 5 cyclosporine A; FTY 5
FTY720; NS 5 not significant.
Figure 3. Representative photomicrograph of histopathologic sections of
the heart. A and D: control mouse; B and E: cyclosporine A-treated
mouse; C and F: FTY720-treated mouse. Hematoxylin and eosin stain,
A,B,C: original magnification 3200, bar 5 50 mm, D,E,F: original
magnification 32, bar 5 1 mm.
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significantly lower in the CsA group than in both the FTY
and the control groups. The difference between the FTY
and control groups was also statistically significant. Simi-
larly, intracardiac IFN-gamma, which inhibits virus repli-
cation (29), was markedly decreased in the CsA group and
only mildly suppressed in the FTY compared with the
control group. Conversely, concentrations of intracardiac
TNF-alpha, one of the proinflammatory cytokines, were
increased in the CsA group, but not in the FTY group,
compared with control.
Intracardiac NO content. In parallel with the changes
observed in TNF-alpha, intracardiac NO content was sig-
nificantly increased in the CsA group, but not in the FTY
group, compared with control (Fig. 6).
DISCUSSION
Superiority of FTY720 over other immunosuppressors in
viral myocarditis. This study showed that the new immu-
nosuppressor FTY had notable therapeutic effects in this
murine model of viral myocarditis, by a prolongation of
survival and attenuation of histologic abnormalities. These
effects were exerted by gentle cardiac immunosuppression,
without the induction of excessive virus replication, despite
the use of relatively high doses of FTY. The doses of CsA
administered were also high because of its peculiar pharma-
cokinetics in mice (30,31). However, a detrimental effect of
CsA in EMCV-induced myocarditis has been observed in
other studies in which lower doses of the drug were used
(6,7).
FTY is reported to be effective in a myosin-induced
autoimmune myocarditis rat model (32). However, another
immunosuppressor, FK506, which is ineffective in a viral
myocarditis murine model (9), is also known to prevent the
progression of myosin-induced autoimmune myocarditis in
a rat model (33,34). A general complication associated with
the use of immunosuppressors in the midst of a viral
infection is uncontrolled virus replication (4,6,35,36), so the
two models of myocarditis should be distinguished in terms
of immunosuppressive therapy. In this study, virus concen-
trations in the heart were significantly increased by CsA,
compared with control, as previously reported (4). This
detrimental effect was not observed with FTY.
Figure 4. Effects of FTY (FTY720) and cyclosporine A (CsA) on
intracardiac virus concentration on day 5 after encephalomyocarditis virus
inoculation in surviving mice. *p , 0.05. NS 5 not significant.
Figure 5. Intracardiac cytokine protein levels on day 5 after encephalo-
myocarditis virus inoculation in surviving mice. A: interleukin (IL)-2; B:
IL-12; C: interferon (IFN)-gamma; D: tumor necrosis factor (TNF)-
alpha. *p , 0.05, **p , 0.01, # p , 0.001. CsA 5 cyclosporine A; FTY 5
FTY720; NS 5 not significant.
Figure 6. Intracardiac nitric oxide (NO) content on day 5 after encepha-
lomyocarditis virus inoculation in surviving mice. #p , 0.001. CsA 5
cyclosporine A; FTY 5 FTY720; NS 5 not significant.
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Characteristic effects of FTY on the expression of cardiac
cytokines, on NO and on virus replication. To investi-
gate the mechanism of this superior effect of FTY, we
measured several cytokines associated with cell-mediated
immunity, and one major proinflammatory cytokine.
Interleukin-2 activates T lymphocyte proliferation, the sup-
pression of which, at a transcriptional level, is known to be
mediated by calcineurin-related immunosuppressant such as
CsA and FK506 (13). In this study, as expected, CsA
prominently suppressed the intracardiac expression of IL-2.
In addition, both IL-12, which promotes differentiation to
the Th1 cell subset (37), and IFN-gamma, a Th1 cytokine
with antiviral activity, were markedly suppressed in the
hearts of CsA-treated mice. This direct inhibition of T
cell-mediated immunity may explain the observed acceler-
ated virus replication. FTY also suppressed the expression of
these three cytokines in the heart, though to a considerably
lesser degree than CsA. The most likely proposed immu-
nosuppressive mechanisms of FTY are an accelerated se-
questration of circulating mature lymphocytes into lymph
nodes and Peyer’s patches (14), and a decrease in peripheral
blood lymphocytes and infiltration into target tissues (15).
In addition, FTY does not directly suppress the proliferative
responses of T cells (16) or the production of IL-2 by
lymphocytes in vitro (14). These mechanisms of action
explain the absence of accelerated virus replication associ-
ated with the FTY treatment. Furthermore, intracardiac
TNF-alpha and NO were proportionally elevated in the
CsA group compared with the control group. Cyclosporine
A is known to suppress TNF-alpha production from lym-
phocytes but not from macrophages in vitro (38). Immu-
nohistochemical analyses have shown TNF-alpha staining
in macrophages within the heart affected by EMCV-
induced myocarditis (39). In addition, TNF-alpha mRNA
was also induced in purified neonatal murine cardiac fibro-
blasts infected with EMCV in vitro (unpublished data),
TNF-alpha concentrations in plasma and in the heart were
increased in EMCV-induced myocarditis (23,25) and treat-
ment with anti-TNF-alpha antibody had a therapeutic
effect in this model (23). From these observations com-
bined, one may hypothesize that excessive viral replication
directly induced TNF-alpha in the hearts of CsA-treated
mice. Nitric oxide is produced by inducible NO synthase
(iNOS), which is induced by proinflammatory cytokines,
including TNF-alpha. Nitric oxide not only has antiviral
effects but also causes myocardial injury. Immunomodulat-
ing drugs, which suppress proinflammatory cytokines and
iNOS (40–42), are therapeutic in EMCV-induced myo-
carditis (25). Increases in TNF-alpha and NO concentra-
tions may also explain, at least in part, the worsening of
heart failure associated with CsA treatment. In contrast, in
our study, FTY did not increase the concentrations of
TNF-alpha or NO.
Opportunistic infection is the most troublesome compli-
cation of immunosuppression in organ transplantation (35).
In this respect, our results suggest that FTY may be superior
to the other immunosuppressors, although its efficacy in the
presence of common opportunistic infectious pathogens
needs to be examined.
Study limitations. In a clinical situation, treatment of viral
myocarditis cannot be initiated at the very onset of infec-
tion. Further experiments, designed with a delay between
virus inoculation and onset of treatment, need to be per-
formed. This study, nevertheless, remains noteworthy for
having observed no increase in virus replication from treat-
ment with FTY. In addition, further studies of the specific
therapeutic effects of FTY are needed, as its precise phar-
macologic properties remain incompletely understood.
In conclusion, this report is the first to describe a
therapeutic effect by an immunosuppressive agent in the
treatment of acute viral myocarditis.
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